Löhn, Matthias, Wirth, Klaus Josef · Journal of translational medicine · 2024 · DOI
This study explores how a specific ion channel called TRPM3, which helps control pain signals and immune cell function, may not work properly in ME/CFS patients. The researchers found that immune cells called natural killer cells have reduced function due to TRPM3 problems, and a medication called low-dose naltrexone (LDN) may help restore this function in laboratory tests. This could explain why some ME/CFS patients report feeling better with LDN treatment.
This research identifies a potential biological mechanism underlying ME/CFS that could explain multiple symptom clusters and suggests a rationale for why some patients respond to low-dose naltrexone therapy. Understanding TRPM3 dysfunction could lead to better diagnostic testing and more targeted treatments for this currently understudied disease.
This study does not prove that TRPM3 dysfunction is the primary cause of ME/CFS—it demonstrates association and potential mechanism in laboratory conditions. The findings do not definitively establish that low-dose naltrexone will be clinically effective for all ME/CFS patients, as in vitro improvements do not always translate to clinical benefit. The paper is a mechanistic review rather than a prospective clinical trial, so causality cannot be firmly established.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.
Primary citation
Löhn, Matthias & Wirth, Klaus Josef (2024). Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone.. Journal of translational medicine. https://doi.org/10.1186/s12967-024-05412-3
BibTeX
@article{mecfsatlas-lhn-2024-potential-pathophysiological,
author = {Löhn, Matthias and Wirth, Klaus Josef},
title = {Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone.},
journal = {Journal of translational medicine},
year = {2024},
doi = {10.1186/s12967-024-05412-3},
note = {PubMed: 38970055},
url = {https://www.mecfsatlas.com/evidence/lhn-2024-potential-pathophysiological},
}Atlas snapshot reference
ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-05-29. https://www.mecfsatlas.com/evidence/lhn-2024-potential-pathophysiological
Contribute
Private, reviewed by a human. Not a public comment thread.